The interaction between the endocannabinoid system and the renin angiotensin system and its potential implication for COVID-19 infection

Alberto Sainz-Cort and Joost H. Heeroma

Abstract

Background: Coronavirus disease 2019 (COVID-19) is spreading fast all around the world with more than fourteen millions of detected infected cases and more than 600,000 deaths by 20th July 2020. While scientist are working to find a vaccine, current epidemiological data shows that the most common comorbidities for patients with the worst prognosis, hypertension and diabetes, are often treated with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Body: Both ACE inhibitors and ARBs induce overexpression of the angiotensin converting enzyme 2 (ACE-2) receptor, which has been identified as the main receptor used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter into the alveolar cells of the lungs. While cannabinoids are known to reduce hypertension, the studies testing the hypotensive effects of cannabinoids never addressed their effects on ACE-2 receptors. However, some studies have linked the endocannabinoid system (ECS) with the renin angiotensin system (RAS), including a cross-modulation between the cannabinoid receptor 1 (CB1) and angiotensin II levels.

Conclusion: Since there are around 192 million people using cannabis worldwide, we believe that the mechanism underlying the hypotensive properties of cannabinoids should be urgently studied to understand if they can also lead to ACE-2 overexpression as other antihypertensive drugs do.

Keywords: COVID-19, Hypertension, Cannabis, ACE-2, SARS-CoV-2, Endocannabinoid
latest insights in the potential interaction of the endocannabinoid system (ECS) and the physiological mechanisms of COVID-19 infection, in order to have an idea of how cannabinoids might affect the prognosis of the disease.

**Main text**

**RAS and COVID-19 infection**

The angiotensin converting enzyme 2 (ACE-2), which belongs to the renin angiotensin system (RAS), has been identified as the main entrance for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to cause COVID-19 infection in the human body (Fang et al. 2020). The RAS regulates the hemodynamics of the body, it has a very important role in the regulation of blood pressure and it has been related to the pathogenesis of hypertension (Miller and Arnold 2019). Antihypertensive drugs that inhibit either angiotensin converting enzymes (ACE) or angiotensin receptors, have been shown to lead to overexpression of ACE-2 (Fang et al. 2020). The use of ACE inhibitors and angiotensin II receptor blockers (ARBs) has been questioned since overexpression of ACE-2 receptors might result in a worse prognosis of the disease (Fang et al. 2020). However, recent scientific evidence raised the controversy whether ACE-2 receptors are actually downregulated or upregulated by ACE inhibitors and ARBs and whether the use of these drugs form a potential benefit or risk for COVID-19 prognosis (Vaduganathan et al. 2020; Cohen et al. 2020; Currman 2020; Fosbøl et al. 2020). In fact, a recent retrospective cohort study showed no association between the use of these drugs and the diagnosis or mortality of COVID-19 infection (Fosbøl et al. 2020). Researchers and doctors advise patients who are already taking antihypertensive drugs to do not stop the medication. This is because stopping the medication could lead to severe health problems while there is not enough scientific evidence to support a potential risk of its use during COVID-19 disease (Vaduganathan et al. 2020).

**Cannabinoids, hypotension and RAS**

The ECS has been linked to cardiovascular modulation in multiple studies, including the modulation of blood pressure (Pacher et al. 2018). In fact, cannabis use and isolated cannabinoid administration (either tetrahydrocannabinol (THC) or cannabidiol (CBD)) is known to induce hypotension in healthy users, among other effects on cardiovascular regulation (Pacher et al. 2018). Hypotensive effects of cannabinoids have been reported to be mediated by the activation of cannabinoid receptor 1 (CB1), which is expressed in vascular smooth muscle and endothelial cells (Pacher et al. 2018). The mechanisms underlying the hypotensive effects of cannabinoids are complex, but animal and human studies point to direct vasorelaxation effects induced by the activation of CB1 and/or to the modulation of vasoactive agonists like angiotensin II (Stanley and O’Sullivan 2014). Not only plant-derived cannabinoids have been linked to hypotension, but also hemp seed oil shows hypotensive effects. Interestingly, these hypotensive effects are mediated by ACE inhibition (Girgih et al. 2014; Ori et al. 2017).

We are not aware of any study linking the ECS to the ACE-2 receptor, but we found some connections between the ECS and the RAS, including some links to the ACE receptor. Cross-talk between the ECS and the RAS has been described in several studies using upregulated RAS rat models, showing that CB1 and angiotensin II type 1 receptor (AT1R) form receptor heteromers with functional interactions and suggesting that hypertensive states are related to lower expression of CB1 and higher levels of angiotensin II (Haspula and Clark 2016; Rozenfeld et al. 2011; Schaich et al. 2016). In line with this and with the effects we previously mentioned concerning cannabis use and hypotension, we found a study examining vascular tissues from rats under different CB1 receptor modulations (activation, blockade and knockout) showing that the activation of CB1 reduces vasoconstrictor and hypertensive effects induced by angiotensin II (Szekeres et al. 2012). Since ARBs are used to reduce hypertension by blocking AT1R and CB1 can modulate AT1R, the hypotensive effects followed by CB1 activation might be induced through similar mechanisms. We also know that these CB1-induced hypotensive effects are related to angiotensin II, which is converted from angiotensin I by ACE receptor (Erdös 1976). Thus, it would be interesting to investigate if CB1-induced hypotension is linked to ARB mechanisms and/or ACE inhibition. If this would be the case, the activation of CB1 by cannabinoids like THC might lead to ACE-2 modulation as it has been showed by other antihypertensive drugs.

It is possible that other cannabinoids which show different interactions with CB1 (i.e. CB1 antagonists) could also lead to ACE-2 modulation. Actually, a recent study demonstrated that high-CBD cannabis extracts can modulate ACE-2 expression in artificial 3D human tissue models, suggesting a therapeutic potential in COVID-19 infection (Wang et al. 2020). However, extracts used in the study had different cannabinoid and terpene profiles, resulting in either upregulation or downregulation of ACE-2 expression. Since the total composition of cannabinoids and terpenes of each extract is unknown, it is not possible to determine which combination of active ingredients can actually downregulate or upregulate ACE-2 expression. In any case, this study would reinforce both
the link between ECS and RAS and the potential effect of cannabis use on ACE-2 receptor expression.

**Conclusion**

Although our analysis is based on existing literature and does not involve direct experimental evidence, we speculate that the hypotensive effects of THC and other CB1 agonist cannabinoids might be related to some of the mechanisms of ARBs and/or ACE inhibitors. Since these hypotensive drugs are shown to modulate ACE-2, we believe it is important to investigate whether cannabinoids have the same effect on ACE-2 expression and its potential consequences related to COVID-19 infection. If our speculations are right, using cannabinoids like THC might not be advisable in the context of a potential COVID-19 infection. Some media suggested cannabinoids could be used to treat the cytokine storm related to COVID-19 infection (Sexton 2020). There is actually preclinical evidence suggesting cannabinoids might protect against cytokine storm and they could improve prognosis in the case of sepsis (Dinu et al. 2020). However, we believe such evidence is not enough to recommend the use of cannabinoids in these cases since there are already other drugs available that have been extensively tested to treat such disorders. In case patients decide to continue using cannabis, it would be advisable to avoid the smoking route of administration and aim for other routes of administration.

Since there are around 192 million people using cannabis worldwide (World Drug Report 2020 2020), we believe that the mechanism underlying the hypotensive properties of cannabinoids should be urgently studied to understand if they can also lead to ACE-2 modulation as other antihypertensive drugs do.

**Abbreviations**

ACE: Angiotensin converting enzyme; ACE-2: Angiotensin converting enzyme 2; ARBs: Angiotensin II type 1 receptor blockers; AT1R: Angiotensin II type 1 receptor; CB1: Cannabinoid receptor 1; CBD: Cannabidiol; COVID-19: Coronavirus disease 2019; ECS: Endocannabinoid system; RAS: Renin angiotensin system; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; THC: Tetrahydrocannabinol

**Acknowledgments**

Not applicable.

**Authors’ contributions**

AS and JH contributed equally to this manuscript. The author(s) read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

AS and JH work for the medical cannabis company GH Medical.

**Author details**

1GH Medical, Carrer d’Osca 4B, Sant Boi de Llobregat, Barcelona, Spain. 2GH Medical, Amsterdam, The Netherlands.

**Received:** 16 April 2020 **Accepted:** 24 July 2020

**Published online:** 31 July 2020

**References**

Cohen JB, Haniff TC, Bress AP, South AM. Relationship between ACE2 and other components of the renin-angiotensin system. Curr Hypertens Rep. 2020;22(7):44.

COVID-19 situation update worldwide, as of 20 July 2020. European Centre for Disease Prevention and Control. Available from: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. [cited 2020 Jul 20].

Curtifan G. Renin-angiotensin-aldosterone inhibitors and susceptibility to and severity of COVID-19. JAMA. 2020;324(2):177–8.

Dinu AR, Rogobete AF, Bratu T, Popovici SE, Bedrea OH, Papurica M, et al. Cannabis sativa revisited-crosstalk between microRNA expression, inflammation, oxidative stress, and Endocannabinoid response system in critically ill patients with sepsis. Cells. 2020;28, 9(2):307.

Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e35.

Erdós EG. Conversion of angiotensin I to angiotensin II. Am J Med. 1976;60(6):749–59.

Fang L, Karakkulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8(4):e21.

Fosbol EL, Butt JH, Østergaard L, Andersson C, Selmer K, Kragholm K, et al. Association of Angiotensin-Converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168–77.

Girgil AT, Alashi A, He R, Malomo S, Aluko RE. Preventive and treatment effects of a hemp seed (Cannabis sativa L.) meal protein hydrolysate against high blood pressure in spontaneously hypertensive rats. Eur J Nutr. 2014;53(5):1237–46.

Haspula D, Clark MA. Heterologous regulation of the cannabinoid type 1 receptor by angiotensin II in astrocytes of spontaneously hypertensive rats. J Neurochem. 2016;139(4):523–36.

Miller AJ, Arnold AC. The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications. Clin Auton Res Off J Clin Auton Res Soc. 2019;29(2):231–43.

Orio LP, Boschin G, Recca T, Morelli CF, Ragona L, Francescato P, et al. New ACE-inhibitory peptides from hemp seed (Cannabis sativa L.) proteins. J Agric Food Chem. 2016;64(18):10482–8.

Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15(3):151–66.

Rozenfeld R, GuptaA, Gagnidze K, Lim MP, Gomes I, Lee-Ramos D, et al. AT1R:CB1, receptor heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. EMBO J. 2011;30(12):2350–63.

Schaich CL, Grabenauer M, Thomas BF, Shaltout HA, Gallagher PE, Howlett AC, et al. Medullary endocannabinoids contribute to the differential resting baroreflex sensitivity in rats with altered brain renin-angiotensin system expression. Front Physiol. 2016;7:207.

Sexton M. Cannabis in the time of coronavirus disease 2019: the Yin and Yang of medicinal cannabis and COVID-19. J Altern Complement Med. 2020;26(6):444–8.

Stanley C, O’Sullivan SE. Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol. 2014;171(6):1361–78.

Szekeres M, Nádasy GL, Turu G, Soltész-Katona E, Tóth ZE, Balla A, et al. Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J Biol Chem. 2012;287(37):31540–50.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653–9.

Wang B, Kovalchuk A, Li D, Inytsky Y, Kovalchuk I, Kovalchuk O. In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues. 2020. Available from: https://www.preprints.org/manuscript/202004.0315/v1. [cited 2020 Apr 27].

World Drug Report 2020. United Nations publication. Available from: //wdr.unodc.org/wdr2020/en/exsum.html. [cited 2020 Jul 20].

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.